As of Wednesday close, Agios Pharmaceuticals Inc.’s (NASDAQ:AGIO) stock was up $0.16, moving up 0.56 percent to $28.83. The average number of shares traded per day over the past five days has been 392,020 shares. 3 times new highs have been achieved over the past 5 days, with a $1.70 gain in that time frame. In the last twenty days, the average volume was 465,055, while in the previous 50 days, it was 560,514.
Since last month, AGIO stock rose 6.94%. Shares of the company fell to $24.70 on 10/24/22, the lowest level in the past month. A 52-week high of $37.71 was reached on 01/05/22 after having rallying from a 52-week low of $16.75. Since the beginning of this year, AGIO’s stock price has dropped by -12.29% or -$4.04, and marked a new high 3 times. However, the stock has declined by -23.55% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
AGIO stock investors should be aware that Agios Pharmaceuticals Inc. (AGIO) stock had its last reported insider trading activity 272 days ago on Feb 25. Washburn Theodore James Jr., the Principal Accounting Officer of the company, disposed of 108 shares for $30.00 on Feb 25. It resulted in a $3,240 divestment by the insider. Washburn Theodore James Jr. sold 233 shares at an average price of $30.81 on Feb 16. The insider now owns 2,549 shares following the transaction. On Feb 14, Principal Accounting Officer Washburn Theodore James Jr. sold 504 shares at $31.25 apiece. The transaction was valued at $15,750.
The stock’s beta is 1.00. Besides these, the trailing price-to-sales (P/S) ratio of 162.18, the price-to-book (PB) ratio of 1.51.
In the three months ended June 29, Agios Pharmaceuticals Inc.’s quick ratio stood at 14.50, while its current ratio was 14.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 87.00% percent.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AGIO’s revenue rose 100.0% to $5.58 million during the quarter, while net income inched up to $3.52 million. While analysts expected Agios Pharmaceuticals Inc. to report -$1.75 quarterly earnings, the actual figure was -$1.68 per share, beating the consensus estimate by 4.00%. During the quarter, the company generated -$89.77 million in EBITDA. The liabilities of Agios Pharmaceuticals Inc. were 130.15 million at the end of its most recent quarter ended June 29, and its total debt was $92.22 million. The value of shareholders’ equity is $54.95 million.
This quick technical analysis looks at Agios Pharmaceuticals Inc.’s (AGIO) price momentum. With a historical volatility rate of 44.26%, the RSI 9-day stood at 55.65% on 23 November.
With respect to its five-day moving average, the current Agios Pharmaceuticals Inc. price is up by +6.27% percent or $1.70. At present, AGIO shares trade +2.63% above its 20-day simple moving average and +13.28% percent above its 100-day simple moving average. However, the stock is currently trading approximately -13.81% below its SMA50 and -3.90% below its SMA200.
Stochastic coefficient K was 80.98% and Stochastic coefficient D was 78.11%, while ATR was 1.50. Given the Stochastic reading of 80.72% for the 14-day period, the RSI (14) reading has been calculated as 53.73%. As of today, the MACD Oscillator reading stands at 0.32, while the 14-day reading stands at 0.84.